Viva Biotech Holdings (HK:1873) has released an update.
Viva Biotech Holdings reported its interim financial results for the six months ending June 30, 2024, revealing a net profit surge to RMB 144.2 million from RMB 13.7 million in the previous year. Despite a slight decrease in revenue and gross profit margin, the company’s adjusted non-IFRS net profit increased, indicating a stronger underlying business performance. These financial highlights demonstrate Viva Biotech’s growth and operational success, excluding certain non-recurring and non-cash items for a more accurate representation of the company’s earnings.
For further insights into HK:1873 stock, check out TipRanks’ Stock Analysis page.